12pm eastern time

Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch Investor Series today announced their agenda is updated for the Virtual Investor Luncheon on Tuesday November 30. Individual investors, finance professionals, and analysts are invited to register now to attend the Luncheon.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

About the Virtual Luncheon:

The luncheon is scheduled to start at 12pm Eastern, Tuesday, November 30 with special guest Bruce Campbell opening the lunch; gain market insight and find investment opportunities all safely in the comfort of your office/home using our latest technology.

AGENDA: (Eastern Time)

12:00PM: Market Commentary - Bruce Campbell, Portfolio Manager at StoneCastle Funds

12:15PM: Quipt Home Medical - TSXV: QIPT

12:30PM: PlantFuel Life - CSE: FUEL

12:45PM: Levitee Labs - CSE: LVT

1:00PM: New "Stocks2Watch" Picks by Bruce Campbell, Portfolio Manager at StoneCastle Funds

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

ABOUT STOCKS2WATCH:

Stocks2Watch hosts online and in-person interactive events for publicly traded companies to meet and present directly with investors. To learn more about Stocks2Watch and view a complete list of events, please visit www.stocks2watch.ca

CONTACT:

Neil Lock,
info@stocks2watch.ca
604-410-4888

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105171

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Levitee Labs

Levitee Labs

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals Keep Reading...
Solvonis Therapeutics

U.S. Patent allowance received for PTSD discovery programme

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces that it has received a Notice of Allowance (the "Allowance") from the United States Patent and Trademark Office ("USPTO")... Keep Reading...
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / lobe sciences ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Change of auditorsOn October 10,... Keep Reading...
Numinus Wellness Announces Change of Auditor

Numinus Wellness Announces Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as... Keep Reading...
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...

Interactive Chart

Latest Press Releases

Related News